Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19GlobeNewsWire • 01/12/21
Are Options Traders Betting on a Big Move in in Vir Biotechnology (VIR) Stock?Zacks Investment Research • 12/22/20
Vir, GSK's experimental COVID-19 treatment moves into a Phase 3 clinical trialMarket Watch • 12/18/20
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19GlobeNewsWire • 12/17/20
Vaccines and Approved Antibodies Dim Vir Biotechnology's Covid Opportunity, Analyst SaysBarrons • 12/04/20
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2020 Financial ResultsGlobeNewsWire • 11/10/20
Vir Biotechnology Publishes New Research Characterizing Variation in the SARS-CoV-2 Spike Protein and Virulence of a Prevalent Immune Evasion Variant, N439KGlobeNewsWire • 11/06/20
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020GlobeNewsWire • 10/27/20
Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?The Motley Fool • 10/18/20
Vir and Alnylam to Webcast Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus Mini-ConferenceGlobeNewsWire • 10/13/20
Nature Publishes New Research from Vir Biotechnology Demonstrating the Capacity of Enhanced Monoclonal Antibodies to Induce Protective Adaptive Immunity to Viral InfectionGlobeNewsWire • 10/09/20
Vir Biotech, GlaxoSmithKline Advance COVID-19 Antibody Treatment Into Global, Late-Stage TrialBenzinga • 10/06/20
Vir Biotechnology, GlaxoSmithKline Expanding Phase 3 Trials For Covid-19 TreatmentInvestors Business Daily • 10/06/20
Vir Biotechnology and GSK announce global expansion to Phase 3 of COMET-ICE study evaluating VIR-7831 for the treatment of COVID-19GlobeNewsWire • 10/06/20
Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal CellGlobeNewsWire • 09/24/20